290 related articles for article (PubMed ID: 32618072)
1. Covid-19: Time for a paradigm change.
Buonaguro FM; Ascierto PA; Morse GD; Buonaguro L; Puzanov I; Tornesello ML; Bréchot C; Gallo RC
Rev Med Virol; 2020 Sep; 30(5):e2134. PubMed ID: 32618072
[No Abstract] [Full Text] [Related]
2. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
3. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
[No Abstract] [Full Text] [Related]
4. Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Yeleswaram S; Smith P; Burn T; Covington M; Juvekar A; Li Y; Squier P; Langmuir P
Clin Immunol; 2020 Sep; 218():108517. PubMed ID: 32585295
[TBL] [Abstract][Full Text] [Related]
5. Immunological co-ordination between gut and lungs in SARS-CoV-2 infection.
Ahlawat S; Asha ; Sharma KK
Virus Res; 2020 Sep; 286():198103. PubMed ID: 32717345
[TBL] [Abstract][Full Text] [Related]
6. Overview of lethal human coronaviruses.
Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W
Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062
[TBL] [Abstract][Full Text] [Related]
7. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
[TBL] [Abstract][Full Text] [Related]
8. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
Theoharides TC
Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
[No Abstract] [Full Text] [Related]
9. Critical COVID-19 disease, homeostasis, and the "surprise" of effective glucocorticoid therapy.
Chrousos GP; Meduri GU
Clin Immunol; 2020 Oct; 219():108550. PubMed ID: 32745524
[No Abstract] [Full Text] [Related]
10. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
Manjaly Thomas ZR; Leuppi-Taegtmeyer A; Jamiolkowski D; Steveling-Klein E; Bellutti-Enders F; Scherer Hofmeier K; Hartmann K
J Allergy Clin Immunol; 2020 Oct; 146(4):786-789. PubMed ID: 32710973
[No Abstract] [Full Text] [Related]
11. Leukotrienes, a potential target for Covid-19.
Citron F; Perelli L; Deem AK; Genovese G; Viale A
Prostaglandins Leukot Essent Fatty Acids; 2020 Oct; 161():102174. PubMed ID: 32977289
[No Abstract] [Full Text] [Related]
12. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
Oscanoa TJ; Romero-Ortuno R; Carvajal A; Savarino A
Int J Antimicrob Agents; 2020 Sep; 56(3):106078. PubMed ID: 32629115
[TBL] [Abstract][Full Text] [Related]
13. After 62 years of regulating immunity, dexamethasone meets COVID-19.
Cain DW; Cidlowski JA
Nat Rev Immunol; 2020 Oct; 20(10):587-588. PubMed ID: 32778829
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19.
Moutsopoulos HM
Ann Rheum Dis; 2020 Sep; 79(9):1253-1254. PubMed ID: 32345616
[No Abstract] [Full Text] [Related]
15. Tissue damage from neutrophil-induced oxidative stress in COVID-19.
Laforge M; Elbim C; Frère C; Hémadi M; Massaad C; Nuss P; Benoliel JJ; Becker C
Nat Rev Immunol; 2020 Sep; 20(9):515-516. PubMed ID: 32728221
[TBL] [Abstract][Full Text] [Related]
16. Potential strategies for combating COVID-19.
Shamim S; Khan M; Kharaba ZJ; Ijaz M; Murtaza G
Arch Virol; 2020 Nov; 165(11):2419-2438. PubMed ID: 32778950
[TBL] [Abstract][Full Text] [Related]
17. Statin therapy and SAR-COV-2: an available and potential therapy?
Abdel-Latif RG; Mohammed S; Elgendy IY
Eur Heart J Cardiovasc Pharmacother; 2020 Sep; 6(5):333-334. PubMed ID: 32379307
[No Abstract] [Full Text] [Related]
18. Treating COVID-19 with colchicine in community healthcare setting.
Della-Torre E; Della-Torre F; Kusanovic M; Scotti R; Ramirez GA; Dagna L; Tresoldi M
Clin Immunol; 2020 Aug; 217():108490. PubMed ID: 32492478
[No Abstract] [Full Text] [Related]
19. Lessons from dermatology about inflammatory responses in Covid-19.
Criado PR; Pagliari C; Carneiro FRO; Quaresma JAS
Rev Med Virol; 2020 Sep; 30(5):e2130. PubMed ID: 32656939
[TBL] [Abstract][Full Text] [Related]
20. Immunologic Features in Coronavirus Disease 2019: Functional Exhaustion of T Cells and Cytokine Storm.
Mahmoudi S; Rezaei M; Mansouri N; Marjani M; Mansouri D
J Clin Immunol; 2020 Oct; 40(7):974-976. PubMed ID: 32648027
[No Abstract] [Full Text] [Related]
[Next] [New Search]
